Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxytran ( (BIXT) ) has provided an update.
On February 18, 2026, Bioxytran amended its Certificate of Designation for Convertible Preferred Stock, filing the change with the Nevada Secretary of State, where it became effective immediately. The amendment restricts any conversion of Convertible Preferred Stock into Common Stock unless the transaction is approved by both the company’s board of directors and a majority of preferred shareholders voting as a single class.
The change, adopted by written consent of the board and a majority of preferred holders, is designed to tighten corporate governance over equity conversions and protect the interests of preferred shareholders. By requiring dual approvals, Bioxytran adds an extra layer of oversight to potential capital structure changes, which could influence future dilution dynamics and align decision‑making among key stakeholders.
More about Bioxytran
Bioxytran operates in the biotechnology and pharmaceutical sector, focusing on the development of therapeutics that leverage advanced biochemistry platforms. The company’s capital structure includes classes of Convertible Preferred Stock and Common Stock, reflecting a financing strategy that relies on preferred equity instruments to support its research and development activities.
Average Trading Volume: 229,714
Technical Sentiment Signal: Sell
Current Market Cap: $3.39M
Learn more about BIXT stock on TipRanks’ Stock Analysis page.